Anti-Mouse GITR Antibody (DTA-1)
Based on 1 Customer Validation
Anti-Mouse GITR Antibody (DTA-1) is a rat derived IgG2b monoclonal agonist antibody targeting mouse GITR. Anti-Mouse GITR Antibody (DTA-1) can activate T cells and B cells to enhance immune response. Anti-Mouse GITR Antibody (DTA-1) selectively enhances Th2 cell effector function through GITR signaling. Anti-Mouse GITR Antibody (DTA-1) may exacerbate allergic reactions. Anti-Mouse GITR Antibody (DTA-1) can be used for researches on cancer and allergic conditions such as colon cancer and allergic asthma. The recommed isotype control of Anti-Mouse GITR Antibody (DTA-1) is Rat IgG2b kappa, Isotype Control (HY-P990682).
For research use only. We do not sell to patients.
- Purity: 98.47%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Rat IgG2b
Mouse
|
NF-κB |
IL-4 |
Anti-Mouse GITR Antibody (DTA-1) (0.0001-100 μg/mL) can be combined with a muGITR-HEK293 transfectant cell line with the EC50 of 0.14 μg/mL[1].
Anti-Mouse GITR Antibody (DTA-1) (0.0001-100 μg/mL, 72-120 h) can enhance TCR triggered T cell proliferation and survival with the EC50 of 0.02 μg/mL[1].
Anti-Mouse GITR Antibody (DTA-1) can activate NF-κB signaling with the EC50 of 0.08 μg/mL[1].
Anti-Mouse GITR Antibody (DTA-1) (5 days) significantly increases the expression of CD86 on the surface of B cells and induces differentiation of CD138+ plasma cells[2].
Anti-Mouse GITR Antibody (DTA-1) (10 μg/mL, 4 days) significantly increases IL-4 secretion in Th2 cells, but has no effect on IFN-γ secretion in Th1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CD4+CD25- T cells
-
Concentration:10 μg/mL
-
Incubation Time:4 days
-
Result:Significant increased the level of IL-4.
Anti-Mouse GITR Antibody (DTA-1) (3.0 mg/kg, i.p., on day 0, 4 and 11 or on day 0, 4, 11 and 18) causes severe allergic reactions in wild type C57BL/6 mice (Healthy or bearing MC-38 tumors)[1].
Anti-Mouse GITR Antibody (DTA-1) (500 μg, i.p., on day 7 and 14) significantly inhibits tumor growth in female Balb/c and CD40−/− mice bearing CT26 or EMT6 tumors[2].
Anti-Mouse GITR Antibody (DTA-1) (1 mg, i.p., single dose, 1 h before the first OVA challenge) exacerbates airway hyperresponsiveness in asthma by selectively enhancing Th2 effector function in male BALB/c mice with a OVA (HY-P0286) induced allergic asthma model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:1×106 MC-38 cells injected wild type C57BL/6 mice (5-6 weeks)[1]
-
Dosage:3.0 mg/kg
-
Administration:Intraperitoneal injection (i.p.), on day 7, 9, and 11
-
Result:Significantly inhibited the increase in tumor volume.
Increased the proportion of CD8+ T cells and regulatory T cells (Treg) within the tumor.
-
Animal Model:Wild type C57BL/6 mice (Healthy or bearing MC-38 tumors) (5-6 weeks)[1]
-
Dosage:3.0 mg/kg for healthy mice, 0.1, 0.3, 1.0, 3.0, and 10.0 mg/kg for mice bearing MC-38 mice
-
Administration:Intraperitoneal injection (i.p.), on day 0, 4, and 11 or on day 0, 4, 11 and 18
-
Result:Caused a decrease in body temperature and behavioral abnormalities in mice.
Increased IL-4 and IgE levels.
-
Animal Model:3×105 CT26 or 1×105 EMT6 cells injected female Balb/c and 3×105 CT26 cells injected CD40−/− mice[2]
-
Dosage:500 μg
-
Administration:Intraperitoneal injection (i.p.), on day 7 and 14
-
Result:Significantly regressed 85% of the tumor in Balb/c mice and 50% of the tumor in CD40−/− mice. Increased the number of CD4+ and CD8+ T cells.
Increased the level of IFN-γ, IL-2, IL-5, and IL-10.
Increased serum IgG1 and IgG2a levels by 20 fold and 7.5 fold and generated tumor reactive IgG1 antibodies.
-
Animal Model:OVA (10 μg, i.p., on day 0 and 7; 10 mg/ml, inhalation, on day 21, 24 and 27) induced male BALB/c mice[3]
-
Dosage:1 mg
-
Administration:Intraperitoneal injection (i.p.), single dose, 1 h before the first OVA challenge
-
Result:Significantly enhanced sensitivity to acetylcholine.
Significantly increased OVA specific IgE levels.
Had no significant change in the number of eosinophils and lymphocyte infiltration.
Significantly increased the levels of IL-5, IL-10 and IL-13.
O35714-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo GITR stimulation
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse GITR Antibody (DTA-1)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Belmar NA, et al. Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice. J Immunol. 2017 Jun 1;198(11):4502-4512. [Content Brief]
[2]. Zhou P, et al. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody. J Immunother. 2010 Oct;33(8):789-97. [Content Brief]
[3]. Motta AC, et al. GITR signaling potentiates airway hyperresponsiveness by enhancing Th2 cell activity in a mouse model of asthma. Respir Res. 2009 Oct 7;10(1):93. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)